STING1 and breast cancer: Second, our results show that cGAS-STING signaling is involved in paclitaxel resistance of breast cancer, and S-72 inhibits STING activation in the paclitaxel-resistant breast cancer cells, but the study was only conducted in MCF7/T cells, and additional models of paclitaxel-resistant breast cancer should be used to verify these results.